Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is -2.37% lower on its value in year-to-date trading and has touched a low of $99.06 and a high of $134.17 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The JAZZ stock was last observed hovering at around $122.54 in the last trading session, with the day’s loss setting it -2.31%.
Currently trading at $120.23, the stock is -2.10% and -0.58% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.39 million and changing -1.89% at the moment leaves the stock 6.53% off its SMA200. JAZZ registered -4.21% loss for a year compared to 6-month gain of 17.61%. The firm has a 50-day simple moving average (SMA 50) of $120.9324 and a 200-day simple moving average (SMA200) of $112.857.
The stock witnessed a -1.93% loss in the last 1 month and extending the period to 3 months gives it a 11.72%, and is -2.37% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 2.56% over the week and 2.60% over the month.
Jazz Pharmaceuticals plc (JAZZ) has around 2800 employees, a market worth around $7.27B and $3.99B in sales. Current P/E ratio is 17.32 and Fwd P/E is 5.49. Profit margin for the company is 11.60%. Distance from 52-week low is 21.37% and -10.39% from its 52-week high. The company has generated returns on investments over the last 12 months (4.49%).
The EPS is expected to grow by 10.39% this year
683.0 institutions hold shares in Jazz Pharmaceuticals plc (JAZZ), with institutional investors hold 101.65% of the company’s shares. The shares outstanding are 60.44M, and float is at 57.91M with Short Float at 7.25%. Institutions hold 98.67% of the Float.
The top institutional shareholder in the company is VANGUARD GROUP INC with over 6.32 million shares valued at $674.82 million. The investor’s holdings represent 10.1103 of the JAZZ Shares outstanding. As of 2024-06-30, the second largest holder is BLACKROCK INC. with 6.15 million shares valued at $655.94 million to account for 9.8274 of the shares outstanding. The other top investors are LSV ASSET MANAGEMENT which holds 2.48 million shares representing 3.9666 and valued at over $264.75 million, while CAPITAL WORLD INVESTORS holds 3.2294 of the shares totaling 2.02 million with a market value of $215.55 million.
Jazz Pharmaceuticals plc (JAZZ) Insider Activity
The most recent transaction is an insider sale by COZADD BRUCE C, the company’s Chairman & CEO. SEC filings show that COZADD BRUCE C sold 1,500 shares of the company’s common stock on Jan 02 ’25 at a price of $123.43 per share for a total of $0.19 million. Following the sale, the insider now owns 0.43 million shares.
Still, SEC filings show that on Dec 02 ’24, COZADD BRUCE C (Chairman & CEO) disposed off 2,000 shares at an average price of $121.17 for $0.24 million. The insider now directly holds 427,025 shares of Jazz Pharmaceuticals plc (JAZZ).
